Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16

Personalized treatment targeting the epidermal growth factor receptor (EGFR) may be a promising new treatment of non-small cell lung cancer (NSCLC). Gefitinib, a tyrosine kinase inhibitor, is the first drug for NSCLC, which unfortunately easily leads to drug resistance. Our study aimed to explore th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ning, Zhang, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844745/
https://www.ncbi.nlm.nih.gov/pubmed/29295721
http://dx.doi.org/10.3727/096504017X15144755633680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844745/
https://www.ncbi.nlm.nih.gov/pubmed/29295721
http://dx.doi.org/10.3727/096504017X15144755633680

Ejemplares similares